Shares of Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) were down 6.6% during trading on Monday . The company traded as low as $12.53 and last traded at $12.69. Approximately 55,240 shares were traded during trading, a decline of 72% from the average daily volume of 198,108 shares. The stock had previously closed at $13.58.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on the stock. Guggenheim initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective on the stock. Stifel Nicolaus began coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $32.00 price target on the stock. Finally, TD Cowen initiated coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating on the stock.
Get Our Latest Report on Sionna Therapeutics
Sionna Therapeutics Stock Performance
The business has a 50-day moving average price of $12.25.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share for the quarter, missing analysts' consensus estimates of ($2.68) by ($0.70).
Institutional Investors Weigh In On Sionna Therapeutics
Several large investors have recently modified their holdings of SION. Jennison Associates LLC bought a new stake in Sionna Therapeutics in the 1st quarter valued at $8,995,000. CenterBook Partners LP bought a new stake in shares of Sionna Therapeutics in the first quarter valued at about $1,195,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Sionna Therapeutics during the first quarter worth about $676,000. Finally, TD Asset Management Inc bought a new position in shares of Sionna Therapeutics during the first quarter worth about $579,000.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
